Inhibition of immune checkpoints prevents injury-induced heterotopic ossification

Abstract

Heterotopic ossification (HO), true bone formation in soft tissue, is closely associated with abnormal injury/immune responses. We hypothesized that a key underlying mechanism of HO might be injury-induced dysregulation of immune checkpoint proteins (ICs). We found that the earliest stages of HO are characterized by enhanced infiltration of polarized macrophages into sites of minor injuries in an animal model of HO. The non-specific immune suppressants, Rapamycin and Ebselen, prevented HO providing evidence of the central role of the immune responses. We examined the expression pattern of ICs and found that they are dysregulated in HO lesions. More importantly, loss of function of inhibitory ICs (including PD1, PD-L1, and CD152) markedly inhibited HO, whereas loss of function of stimulatory ICs (including CD40L and OX-40L) facilitated HO. These findings suggest that IC inhibitors may provide a therapeutic approach to prevent or limit the extent of HO.

References

[1] Sakellariou VI, Grigoriou E, Mavrogenis AF, Soucacos PN, Papagelopoulos PJ. Heterotopic ossification following traumatic brain injury and spinal cord injury: insight into the etiology and pathophysiology. J. Musculoskelet. Neuron. Interact., 2012, 12:230-240

[2] Xu, R., Hu, J., Zhou, X. & Yang, Y. Heterotopic ossification: mechanistic insights and clinical challenges. Bone 109, 134–142 (2018).

[3] Pacifici M. Acquired and congenital forms of heterotopic ossification: new pathogenic insights and therapeutic opportunities. Curr. Opin. Pharmacol., 2018, 40:51-58

[4] Dey D et al. The traumatic bone: trauma-induced heterotopic ossification. Transl. Res., 2017, 186:95-111

[5] Legosz P, Drela K, Pulik L, Sarzynska S, Maldyk P. Challenges of heterotopic ossification-molecular background and current treatment strategies. Clin. Exp. Pharm. Physiol., 2018, 45:1229-1235

[6] Hurlimann M et al. Influence of surgical approach on heterotopic ossification after total hip arthroplasty - is minimal invasive better? A case control study. BMC Musculoskelet. Disord., 2017, 18

[7] Zeckey C, Hildebrand F, Frink M, Krettek C. Heterotopic ossifications following implant surgery–epidemiology, therapeutical approaches and current concepts. Semin. Immunopathol., 2011, 33:273-286

[8] Huning I, Gillessen-Kaesbach G. Fibrodysplasia ossificans progressiva: clinical course, genetic mutations and genotype-phenotype correlation. Mol. Syndromol., 2014, 5:201-211

[9] Jiang JX. Posttraumatic stress and immune dissonance. Chin. J. Traumatol., 2008, 11:203-208

[10] Czura CJ, Friedman SG, Tracey KJ. Neural inhibition of inflammation: the cholinergic anti-inflammatory pathway. J. Endotoxin Res., 2003, 9:409-413

[11] Kan L et al. Dysregulation of local stem/progenitor cells as a common cellular mechanism for heterotopic ossification. Stem Cells, 2009, 27:150-156

[12] Kan L, Mutso AA, McGuire TL, Apkarian AV, Kessler JA. Opioid signaling in mast cells regulates injury responses associated with heterotopic ossification. Inflamm. Res., 2014, 63:207-215

[13] Ranganathan K et al. The role of the adaptive immune system in burn-induced heterotopic ossification and mesenchymal cell osteogenic differentiation. J. Surg. Res., 2016, 206:53-61

[14] Jung K, Choi I. Emerging co-signaling networks in T cell immune regulation. Immune Netw., 2013, 13:184-193

[15] Sperk, M., Domselaar, R. V. & Neogi, U. Immune checkpoints as the immune system regulators and potential biomarkers in HIV-1 infection. Int. J. Mol. Sci. 19, E2000 (2018).

[16] Riva, A. & Chokshi, S. Immune checkpoint receptors: homeostatic regulators of immunity. Hepatol. Int. 12, 223–236 (2018).

[17] Cicerone C, Nenna R, Pontone S. Th17, intestinal microbiota and the abnormal immune response in the pathogenesis of celiac disease. Gastroenterol. Hepatol. Bed Bench, 2015, 8:117-122

[18] Kohn J. Abnormal immune response in burns. Postgrad. Med. J., 1972, 48:335-337

[19] Jasiulionis MG. Abnormal epigenetic regulation of immune system during aging. Front. Immunol., 2018, 9:197

[20] Qureshi AT et al. Inhibition of mammalian target of rapamycin signaling with rapamycin prevents trauma-induced heterotopic ossification. Am. J. Pathol., 2017, 187:2536-2545

[21] Wendel A, Kuesters S, Tiegs G. Ebselen–an in vivo immune response modifier. Biomed. Environ. Sci., 1997, 10:253-259

[22] Kan L, Hu M, Gomes WA, Kessler JA. Transgenic mice overexpressing BMP4 develop a fibrodysplasia ossificans progressiva (FOP)-like phenotype. Am. J. Pathol., 2004, 165:1107-1115

[23] Kan L et al. Substance P signaling mediates BMP-dependent heterotopic ossification. J. Cell Biochem., 2011, 112:2759-2772

[24] Kan L, Peng CY, McGuire TL, Kessler JA. Glast-expressing progenitor cells contribute to heterotopic ossification. Bone, 2013, 53:194-203

[25] Kan, C. et al. Gli1-labeled adult mesenchymal stem/progenitor cells and hedgehog signaling contribute to endochondral heterotopic ossification. Bone 109, 71–79 (2018).

[26] Kraft CT et al. Trauma-induced heterotopic bone formation and the role of the immune system: a review. J. Trauma Acute Care Surg., 2016, 80:156-165

[27] Kan, C. et al. Conserved signaling pathways underlying heterotopic ossification. Bone 109, 43–48 (2018).

[28] Kan C et al. BMP-dependent, injury-induced stem cell niche as a mechanism of heterotopic ossification. Stem Cell Res. Ther., 2019, 10:14

[29] Kan L, Kessler JA. Evaluation of the cellular origins of heterotopic ossification. Orthopedics, 2014, 37:329-340

[30] Wang, H., Shore, E. M., Pignolo, R. J. & Kaplan, F. S. Activin A amplifies dysregulated BMP signaling and induces chondro-osseous differentiation of primary connective tissue progenitor cells in patients with fibrodysplasia ossificans progressiva (FOP). Bone 109, 218–224 (2018).

[31] Agarwal S et al. Scleraxis-lineage cells contribute to ectopic bone formation in muscle and tendon. Stem Cells, 2017, 35:705-710

[32] Kaplan FS, Pignolo RJ, Shore EM. Granting immunity to FOP and catching heterotopic ossification in the act. Semin. Cell Dev. Biol., 2016, 49:30-36

[33] Haupt J et al. mutation alters mechanosensing and tissue stiffness during heterotopic ossification. Mol. Biol. Cell, 2019, 30:17-29

[34] Rodenberg E et al. Matrix metalloproteinase-9 is a diagnostic marker of heterotopic ossification in a murine model. Tissue Eng. A, 2011, 17:2487-2496

[35] Crowgey EL, Wyffels JT, Osborn PM, Wood TT, Edsberg LE. A systems biology approach for studying heterotopic ossification: proteomic analysis of clinical serum and tissue samples. Genomics Proteomics Bioinformatics, 2018, 16:212-220

[36] Davis EL et al. Location-dependent heterotopic ossification in the rat model: the role of activated matrix metalloproteinase 9. J. Orthop. Res., 2016, 34:1894-1904

[37] Meyers C et al. Heterotopic ossification: a comprehensive review. JBMR Plus, 2019, 3

[38] Levesque JP et al. Macrophages driving heterotopic ossification: convergence of genetically-driven and trauma-driven mechanisms. J. Bone Miner. Res., 2018, 33:365-366

[39] Convente MR et al. Depletion of mast cells and macrophages impairs heterotopic ossification in an Acvr1^R206H mouse model of fibrodysplasia ossificans progressiva. J. Bone Miner. Res., 2018, 2:269-282

[40] Kraft CT et al. Trauma-induced heterotopic bone formation and the role of the immune system: a review. J. Trauma Acute Care Surg., 2016, 80:156-165

[41] Loder SJ et al. Characterizing the circulating cell populations in traumatic heterotopic ossification. Am. J. Pathol., 2018, 188:2464-2473

Funding

U.S. Department of Health & Human Services | NIH | Center for Scientific Review (NIH Center for Scientific Review)(RO1 AR066539)